Delpeyroux F, Guillot S, Szendröi A, Balanant J, Caro V, Cuervo N, Chevaliez S, Dahourou G, Crainic R
Institut Pasteur, Paris, France.
Bull Soc Pathol Exot. 2000 Jul;93(3):193-7.
To eradicate poliomyelitis and poliovirus, intensive vaccination campaigns with oral polio-vaccine (OPV) have been organised. Eradication campaigns may well be successful because the antiviral immunity and the local intestinal immunity due to OPV in particular avoids and/or limits poliovirus circulation. These campaigns give interesting opportunities for studying the impact of viral vaccines on the viral world in terms of ecological and genetic virology. The pre-eradication phase we are now entering brings with it two kinds of problems. First, the major disadvantage of OPV is the genetic and phenotypic variability of the vaccine strains. This variability leads to the spread of potentially pathogenic strains, which can be implicated in vaccine-associated paralytic poliomyelitis (VAPP). Genetic changes are characterised by point mutations and by genetic exchanges among OPV strains, between OPV and wild strains and perhaps between poliovirus and non-polio enteroviruses (ENPV). The fact that a few OPV mutant strains have been shown to multiply and/or to circulate for long periods suggests that OPV could sustain a reservoir of pathogenic poliovirus strains. Second, there are ecological considerations. The disappearance of wild poliovirus through OPV vaccination could be due not only to antiviral local immunity but also to competition between OPV strains and wild strains for infecting the digest tract. Moreover, a competition between OPV and other enteroviruses may take place in a common ecological niche. To our knowledge, the possible impact of intensive OPV vaccination campaigns on the ENPV populations has never been considered. Because the goal of poliovirus eradication may be reached in the near future, there is worry as to the possible evolution of ENPV towards highly epidemic and pathogenic strains. This is leading those laboratories involved in poliomyelitis surveillance not only to search for remaining wild poliovirus strains but also to study the possible long-term circulation of OPV strains and to develop efficient ENPV surveillance.
为了根除脊髓灰质炎和脊髓灰质炎病毒,已组织了口服脊髓灰质炎疫苗(OPV)强化免疫运动。根除运动很可能会取得成功,因为OPV所产生的抗病毒免疫力和局部肠道免疫力尤其能够避免和/或限制脊髓灰质炎病毒的传播。这些运动为从生态和基因病毒学角度研究病毒疫苗对病毒世界的影响提供了有趣的机会。我们目前正在进入的根除前阶段带来了两类问题。首先,OPV的主要缺点是疫苗株的基因和表型变异性。这种变异性导致潜在致病株的传播,这可能与疫苗相关麻痹性脊髓灰质炎(VAPP)有关。基因变化的特征是点突变以及OPV株之间、OPV与野生株之间甚至脊髓灰质炎病毒与非脊髓灰质炎肠道病毒(ENPV)之间的基因交换。一些OPV突变株已被证明能长时间增殖和/或传播,这一事实表明OPV可能维持致病性脊髓灰质炎病毒株的储存库。其次,存在生态学方面的考虑。通过OPV疫苗接种使野生脊髓灰质炎病毒消失,可能不仅是由于抗病毒局部免疫,还可能是由于OPV株与野生株在感染消化道方面的竞争。此外,OPV与其他肠道病毒之间可能在共同的生态位中发生竞争。据我们所知,强化OPV免疫运动对ENPV种群可能产生的影响从未得到过考虑。由于脊髓灰质炎病毒根除目标可能在不久的将来实现,人们担心ENPV可能演变为高度流行和致病的毒株。这使得参与脊髓灰质炎监测的实验室不仅要寻找剩余的野生脊髓灰质炎病毒株,还要研究OPV株可能的长期传播情况,并开展有效的ENPV监测。